Pharmacokinetics of engineered human monomeric and dimeric CH2 domains.
Therapeutic monoclonal antibodies have several advantages over small molecule drugs and small proteins and peptides, including a long serum half-life. The long serum half-life of IgG is due, in part, to its molecular weight (150kDa) and its ability to bind FcRn. Both the CH2 and CH3 domains of Fc are involved in FcRn binding. Antibody fragments and antibody-like scaffolds have improved penetration into tissues due to their small size, yet suffer from a short serum half-life of less than one hour. The human CH2 domain (CH2D) of IgG1 retains a portion of the FcRn binding site, is amenable to modification for target binding, and may represent the smallest antibody-like scaffold retaining a relatively long serum half-life. Here we describe the generation of a dimeric CH2D (dCH2D) and determination of its pharmacokinetics (PK), as well as the PK of wild-type monomeric CH2D (mCH2D) and a short stabilized CH2D variant (ssCH2D) in normal B6 mice, human FcRn transgenic mice and cynomolgus macaques. The elimination half-life of dCH2D was 9.9, 10.4 and 11.2 hours, and that of ssCH2D was 13.1, 9.9 and 11.4 hours, in B6 mice, hFcRn mice and cynomolgus macaques, respectively. These half-lives were slightly longer than that of mCH2D (6.9 and 8.8 hours) in B6 and hFcRn mice, respectively. These data demonstrate that engineered CH2D-based variants have relatively long serum half-lives, making them a unique scaffold suitable for development of targeted therapeutics.
Research Corporation Technologies, Inc., Tucson, AZ USA. kgehlsen@rctech.com
Kurt
K
Gehlsen
Rui
R
Gong
Dave
D
Bramhill
David
D
Wiersma
Shaun
S
Kirkpatrick
Yangping
Y
Wang
Yang
Y
Feng
Dimiter S
DS
Dimitrov
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000276:immunology / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001665:Binding Sites / Q000235:genetics / Q000276:immunology; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D006207:Half-Life; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry* / Q000235:genetics / Q000276:immunology; D008252:Macaca fascicularis; D008657:Metabolic Clearance Rate; D051379:Mice; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009154:Mutation; D015202:Protein Engineering; D055503:Protein Multimerization; D017434:Protein Structure, Tertiary; D013997:Time Factors
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G